Status:
RECRUITING
Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Hepatoid Adenocarcinoma of Stomach
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to learn if treatment modality including albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules (SOX) and sintilimab works to treat...
Eligibility Criteria
Inclusion
- The histological type of gastric hepatoid adenocarcinoma was confirmed by pathological biopsy；
- HER2 negative (Immunohistochemistry: 0);
- Patients with clinical stage II-III;
- Those who are expected to complete R0 excision;
- ECOG score 0\~1;
- Generally in good condition, perioperative treatment and surgical resection can be tolerated;
- Patients were enrolled voluntarily.
Exclusion
- Combined with other malignant tumors (excluding thyroid papillary carcinoma, facial basal cell carcinoma and other low-grade malignant tumors); -Patients with obstruction, bleeding, etc. who need surgical intervention after evaluation by clinicians;
- dMMR/MSIH status；
- Received other anti-tumor therapy before enrollment.
Key Trial Info
Start Date :
September 18 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 20 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07178340
Start Date
September 18 2025
End Date
September 20 2028
Last Update
December 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Cancer Hospital & Institute
Beijing, China